Blood test may predict amyloidosis treatment success in days
NCT ID NCT06627309
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at whether a rapid drop in a blood marker called dFLC can predict a complete response in people with AL amyloidosis treated with daratumumab-based therapy. Researchers will follow 50 patients to see if early changes in dFLC levels match up with later treatment success. The goal is to find a simple way to guide treatment decisions early on.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Daratumumab, bortezomib, and dexamethasone
- What this could lead to
- If successful, this could help doctors quickly tell if a patient is responding to treatment, allowing for faster adjustments and better outcomes.
- What could go wrong
- This is a small, early-stage study with only 50 participants. The blood marker may not reliably predict long-term response, and results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC AL AMYLOIDOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing Anzhen Hospital
RECRUITINGBeijing, Beijing Municipality, 101118, China
-
Chinese PLA Eastern Theater General Hospital
RECRUITINGNanjing, Jiangsu, China
-
First Affiliated Hospital of Harbin Medical University
RECRUITINGHarbin, Heilongjiang, China
-
Fuxing Hospital affiliated to Capital Medical University
RECRUITINGBeijing, Beijing Municipality, 100045, China
-
Peking University First Hospital
RECRUITINGBeijing, Beijing Municipality, China
-
Peking University People's Hospital
RECRUITINGBeijing, Beijing Municipality, 100044, China
-
Shengjing Hospital of China Medical University
RECRUITINGShenyang, Liaoning, China
-
The First Affiliated Hospital of Xi'an Jiao Tong University
RECRUITINGXi'an, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.